Research Paper Volume 15, Issue 22 pp 13329—13344

circSLCO1B7 suppresses the malignant progression of hepatocellular carcinoma via the miR-556-3p/DAB2IP axis

class="figure-viewer-img"

Figure 7. Overexpression of circSLCO1B7 inhibited the growth of HCC cells in vivo. (A, B) Nude mice were injected with LV-control and LV-circ (circSLCO1B7) PLC/PRF/5 cells. After 36 days, the nude mice and tumor tissues were treated and photographed. (C) The size of tumor tissues was measured every 4 days. The growth curve was made after 36 days. (D) The weight of tumor tissues was measured. (E, F) qRT–PCR was used to detect the expression of circSLCO1B7 and DAB2IP in the LV-circ group compared to the LV-control group. (G) Western blot analysis of the protein levels of E-cadherin, Vimentin and Snail in the LV-circ group compared to the LV-control group. (H) HE and IHC experiments showed the difference between the LV-circ group and LV-control group and the expression of DAB2IP, E-cadherin, Vimentin and Snail. (I) A schematic diagram on the mechanism of circSLCO1B7 affecting the progression of HCC. All data are presented as the means ± SD. *P < 0.05, ***P < 0.001, ****P < 0.0001.